Navigation Links
European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Date:9/25/2007

BOXMEER, The Netherlands, September 26 /PRNewswire/ -- A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund the research and the development of the new vaccine. The so-called FluVac project will be coordinated by Nobilon International BV which is part of Organon, the human healthcare business unit of Akzo Nobel.

The recent epidemic of a new pathogenic strain of H5N1 influenza in birds in Asia has fuelled further concerns about a potential pandemic influenza outbreak. In the event of an influenza pandemic, large quantities of a highly effective vaccine will be needed on short notice. A European consortium consisting of Nobilon International BV (the Netherlands), Protherics PLC (United Kingdom), Retroscreen Virology Ltd (United Kingdom), Erasmus Medical Centre (the Netherlands) and Landspitali University Hospital (Iceland) has agreed to collaborate on the development of such a vaccine. The collaboration takes advantage of complementary expertise and technology of these renowned parties.

Non-clinical studies with a novel H5N1 vaccine developed by Nobilon and containing CoVaccine HT(TM), a powerful adjuvant from Protherics, have produced encouraging results to date. This has resulted in the successful application of an EU grant to develop this promising vaccine through proof-of-concept in phase I and II clinical trials. Upon successful achievement of proof-of-concept, the consortium intends to pursue further clinical development.

Dr. Luuk Hilgers, scientific coordinator for the project on behalf of Nobilon, stated: "In the event of an influenza pandemic, vaccination will play a key role in its control. Therefore, availability of a sufficient number of vaccine doses will be critical. In this project, we will explo
'/>"/>

SOURCE N.V. Organon
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
6. Tired of the spin? ExpertVoter website makes candidate selection easier
7. Innovation expert speaks on the business-IT balancing act
8. Brady appoints GE efficiency expert as CTO
9. Innovation expert says Milwaukee has all the tools
10. Microsoft rewards Berbee for project management expertise
11. Sonic Foundry creates search engine for 7,000 expert video presentations

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...f., Nov. 6 Intarcia Therapeutics, ... 650 (DUROS® continuous delivery of exenatide...the Ninth Annual Diabetes Technology Meeting in Sa...com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, Co...CA 650 Lowers Plasma Glucose, HbA1c and Reduces We...
(Date:11/5/2009)...olo., Nov. 5 The endangered black-...stern U.S. This rare carnivore feeds on prairie d...ague and often entire population die-offs in towns...) has implemented a ferret breeding program and ha...ir formerly native habitat. Unfortunately, plague...
(Date:11/5/2009)...ll on Thursday, November 5, 2009 at 4:30 p.m. East...PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals,...I ) today reported unaudited financial results for... 30, 2009 and reviewed the Company,s highlights fo...onsolidated results reflect the operations of Onco...
(Date:11/5/2009)...exas, Nov. 5 Wound Manag...that it has entered into a Letter of Intent to pur...lth Technologies, Inc. (OTC Bulletin Board: VHGI)....in cash and debt, 4,000,000 shares of WNDM and a r... the Veriscrip technology being acquired from VHGI...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
...sia/ -- Simcere Pharmaceutical Group,("Simcere" or...urer and supplier,of branded generic and innovativ...ed financial results for the quarter ended March 3...creased to RMB442.5 million (US$64.8 million) for ...lion for the corresponding, period in 2008, ...
...ls announces it has signed an agreement with HUYA ... enabling and accelerating global codevelopment of...ginating in China. , , Through this agreement, S...omprehensive Chinese molecule portfolio, focusing ...ea. As some of these molecules are already in adv...
...oratories, Inc., an emerging specialty pharmaceuti...ausea and vomiting (OINV) in opioid pharmaceutical... Exploratory Bioequivalence Study on CL-108, Charl...ising data on our immediate-release low-dose antie...icer at Charleston Laboratories, "and confirm our ...
Other Biology Technology:Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 2Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 3Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 4Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 6Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 7Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 8Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 9Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 10Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 11Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 2Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 3Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108 2
(Date:11/5/2009)...n, Conn.Researchers at Yale University have develo...ody,s immune response to HIV and HIV-infected cell...ings, published online in the Journal of the Amer...eutic approaches for these diseases. , The mole...ing HIV" (ARM-H) and "antibody-recruiting molecule...
(Date:11/4/2009)...PHIA Although scientists are reluctant to officia...d, evidence continues to grow about its protective...ed in Cancer Prevention Research , a journal of t... suggests some reduction in oral cancer. , Vass...ine in the Department of Thoracic/Head and Neck Me...
(Date:11/4/2009)...affic corridors in the cities of Long Beach and Ri...on of preventable childhood asthma, and the true i...isease has likely been underestimated, according t...rnia (USC). , The study, which appears in an on...alth , estimated that nine percent of all childhoo...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Any Day OK for Heart Bypass Surgery 58127 1Any Day OK for Heart Bypass Surgery 58127 2Data Strategy Invited to Become a Member of VMware 26apos 3Bs Partner Technical Advisory Board 28PTAB 29 58123 1Data Strategy Invited to Become a Member of VMware 26apos 3Bs Partner Technical Advisory Board 28PTAB 29 58123 2Healthcare Breach Notification Rules Take Effect 3B ID Experts Offers Complimentary Tool to Measure Organizations Breach Index 58119 1Healthcare Breach Notification Rules Take Effect 3B ID Experts Offers Complimentary Tool to Measure Organizations Breach Index 58119 2Healthcare Breach Notification Rules Take Effect 3B ID Experts Offers Complimentary Tool to Measure Organizations Breach Index 58119 3
...reat idea or invention but don,t know where to tur...ing day of four workshops for first-time entrepren...Center and the Alumni Association of NJIT. Set fo...30 a.m. 3 p.m., the event will feature many oppor...ch that dream. , "I Have an Idea, Now What?" is...
...ase, MDCigarette smoking during pregnancy is assoc...ernal and fetal thyroid function, according to a n... Society,s Journal of Clinical Endocrinology & Me...f cigarette smoking on thyroid function of two gro... in the first trimester and the other in the third...
...lle, NY, January 12, 2009The Academy of Breastfeed...ite, Facebook, would be well advised to review its...rs. Such a policy perpetuates the notion that brea... from public viewing, a misguided and antiquated c...It further perpetuates the idea that formula feedi...
Other Biology News:Entrepreneurs wanted for NJIT workshops about how to launch a business 2
Cat IgA ELISA Kit from Bethyl Laboratories
Cat IgM ELISA Kit from Bethyl Laboratories
Phosphatase Colorimetric Assay Kit from BioAssay Systems
Horse IgGb ELISA Kit from Bethyl Laboratories
Biology Products: